EMAIL THIS PAGE TO A FRIEND

Arteriosclerosis, thrombosis, and vascular biology

Erythrocyte-derived microvesicles amplify systemic inflammation by thrombin-dependent activation of complement.


PMID 24311376

Abstract

Transfusion of aged blood has been associated with increased morbidity and mortality in critically ill patients. During storage, erythrocytes release increasing numbers of microvesicles (red blood cell-derived microvesicles [RBC-MV]). We hypothesized that RBC-MV mediate some of the deleterious effects of aged blood transfusions. We established a murine transfusion model using RBC-MV purified from aged mouse erythrocytes. Injection of RBC-MV into healthy mice had no effect. However, they aggravated pulmonary leukocyte sequestration and peripheral blood leukopenia induced by lipopolysaccharides. Lipopolysaccharide-induced proinflammatory cytokines were significantly increased in plasma after RBC-MV injection. These effects were not seen in C5aR-deficient mice. In vitro, RBC-MV bound C3 fragments after incubation with plasma but failed to bind immunoglobulins, C1q, or mannose-binding lectin. Preventing thrombin generation inhibited complement activation in vitro and in vivo and reversed the proinflammatory effects of RBC-MV in lipopolysaccharide-primed mice. Finally, the RBC-MV-induced phenotype was recapitulated using phosphatidylserine-expressing liposomes, suggesting that surface expression of phosphatidylserine by RBC-MV was mechanistically involved. These results point toward a thrombin-dependent mechanism of complement activation by RBC-MV independent of the classical, lectin, or alternative pathway. Besides identifying RBC-MV as potential mediators of transfusion-related morbidity, our findings may be relevant for other inflammatory disorders involving intravascular microvesicle release, for example, sickle cell disease or thrombotic microangiopathy.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

T4648 Thrombin from bovine plasma, lyophilized powder, 40-300 NIH units/mg protein (biuret)
T7513 Thrombin from bovine plasma, lyophilized powder, ≥2,000 NIH units/mg protein (E1%/280 = 19.5)
T6634 Thrombin from bovine plasma, lyophilized powder, 600-2,000 NIH units/mg protein (biuret)
T9549 Thrombin from bovine plasma, powder, cell culture tested, ≥1,500 NIH units/mg protein (E1%/280 = 19.5)
T7201 Thrombin from bovine plasma, lyophilized powder, ≥2,000 NIH units/mg protein (E1%/280 = 19.5)
T7326 Thrombin from bovine plasma, ≥60 NIH units/mg protein (biuret)
T6884
Thrombin from human plasma, lyophilized powder, ≥2,000 NIH units/mg protein (E1%/280, 18.3)
T7009
Thrombin from human plasma, lyophilized powder, ≥1,000 NIH units/mg protein (E1%/280, 18.3)
T1063
Thrombin from human plasma, lyophilized powder, ≥2800 NIH units/mg protein (E1%/280, 18.3)
T8885
Thrombin from human plasma, lyophilized powder, Suitable for routine use in the thrombin time test
T4393
Thrombin from human plasma, lyophilized powder, 1500-3500 NIH units/mg protein (E1%/280, 18.3), cell culture tested
T7572
Thrombin from human plasma, 400-1000 NIH units/mg protein
T5772 Thrombin from rat plasma, lyophilized powder, ≥1,000 units/mg protein (biuret)
T9326
Thrombin human, BioUltra, recombinant, expressed in HEK 293 cells, aqueous solution, ≥95% (SDS-PAGE)